Ponatinib versus Allogeneic Stem Cell Transplant for Patients with CML or Ph+ ALL with the T315I Mutation


Ponatinib versus Allogeneic Stem Cell Transplant for Patients with CML or Ph+ ALL with the T315I Mutation
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Nicolini FE et al. The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with the T315I mutation. Proc ASH 2015;Abstract 480.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.